Abstract:Background Although staphylokianse (SAK) is among the most promising blood dissolving agents, it is far from ideal. It is interesting to hypothesize that the clot lysis efficacy of SAK can be enhanced with direct active platelet binding ability, and at the same time the rethrombosis complication after successful recanalization can be minimized with an antiplatelet aggregation activity. The present study was performed to characterize the functional properties of RGD-SAK, a novel mutant of staphylokinase (SAK). Results By using site-directed mutagenesis, an Arg-Gly-Asp (RGD) motif was engineered in the staphylokinase (SAK). This mutant of SAK designated RGD-SAK was expressed, purified and characterized. Biochemical analysis indicated that RGD-SAK maintained the similar structure and the fibrinolytic function of SAK. Measurement of platelet binding activity in vitro demonstrated that RGD-SAK had a much higher affinity with platelets than SAK. In vitro platelet-rich clot lysis assay demonstrated that the engineered mutant outperformed the non-manipulated SAK. The time required for 50% platelet-rich clot lysis and the concentration required to obtain 50% clot lysis (C 50 ) were reduced significantly across different concentrations of RGD-SAK comparing with SAK. Meanwhile, RGD-SAK was found to inhibit ADP-induced platelet aggregation in a concentration-dependent manner while SAK had negligible effect on platelet aggregation. Conclusion RGD-SAK possessed the bifunction to target platelet-rich clots and to block platelets aggregation, and thus may serve as a more potential thrombolytic agent with platelet-targeted thrombolytic and antiplatelet aggregation activities in compared with SAK.

Gene Construction, Expression, Purification and Activity Analysis of Anti-platelet Aggregation Peptide RGD226

Inhibition of Platelet Aggregation of A Mutant Proinsulin Molecule Engineered by Introduction of A Native Arg-Gly-Asp Sequence

Platelet aggregation inhibitory activity of mutant proinsulin with C-peptide replaced by CRGDSC sequence

An RGD-Containing Peptide Derived from Wild Silkworm Silk Fibroin Promotes Cell Adhesion and Spreading

Effect of disulfide bond on the conformation and anticoagulant activity of an Arg-Gly-Asp motif displayed on a mutant insulin protein framework

[Fermentation, Purification and Identification of Recombinant RGD-Hirudin].

[Effect of Arg-Gly-Asp-Ser (RGDS) Peptide on ADP-induced Signal Transduction of Activated Rat Platelet].

Efficient targeted anticoagulant with active RGD motif.

A Novel Hirudin Derivative Characterized with Anti-Platelet Aggregations and Thrombin Inhibition.

Construction and Expression of Chimeric Antithrombotics with Hirudin and RGD Sequence

Inhibitory Effect of Arg-Gly-Asp-Ser Peptide on Phosphorylation of Glycoprotein IIb/IIIa in Activated Rat Platelets

Construction of Fusion Recombinant Plasmid Coding for RGD Peptide and Urokinase B Chain, Its Expression in Escherichia coil and Preliminary Characterization of Its Biological Activity

Prokaryotic Expression of SA-hirudin-RGD Fusion Proteinand Identification of Its Anticoagulant and Anti-platelet Aggregation Function

[Construction of fusion recombinant plasmid coding for RGD peptide and urokinase B chain, its expression in Escherichia coli and preliminary characterization of its biological activity]

Characterization of a novel bifunctional mutant of staphylokinase with platelet-targeted thrombolysis and antiplatelet aggregation activities

Effect of amino acids near the RGD sequence on binding activities between αIIbβ3 integrin and fibrinogen in the presence of RGD-containing synthetic peptides from elegantin and angustatin

[Purification of a Small Peptide SV-PP-3 from the Venom of Agkistrodon Blomhoffii Siniticus and Its Inhibition of Platelet Aggregation].

Functional Properties of a Novel Mutant of Staphylokinase with Platelet-Targeted Fibrinolysis and Antiplatelet Aggregation Activities

Synthesis of RGD Containing Peptides and Their Bioactivities.

Construction and Characterization of Novel Staphylokinase Variants with Antiplatelet Aggregation Activity and Reduced Immunogenecity.

Inhibition of Platelet Aggregation by Polyaspartoyl L-Arginine and Its Mechanism